These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 14619771)

  • 1. FDA approves test for heart-disease marker.
    Health News; 2003 Oct; 9(10):10. PubMed ID: 14619771
    [No Abstract]   [Full Text] [Related]  

  • 2. Inflammatory markers of coronary risk.
    Rader DJ
    N Engl J Med; 2000 Oct; 343(16):1179-82. PubMed ID: 11036126
    [No Abstract]   [Full Text] [Related]  

  • 3. New tests for heart disease: promise but no payoff. Three new blood tests designed to detect early heart disease aren't quite ready for prime time.
    Harv Heart Lett; 2005 Jul; 15(11):6--7. PubMed ID: 16149177
    [No Abstract]   [Full Text] [Related]  

  • 4. New test predicts heart risk.
    FDA Consum; 2003; 37(5):6. PubMed ID: 14666894
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions.
    Iribarren C
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):5-6. PubMed ID: 16373620
    [No Abstract]   [Full Text] [Related]  

  • 6. Stopping stroke before it strikes.
    Bloom S
    J Clin Invest; 2005 Aug; 115(8):1968. PubMed ID: 16075036
    [No Abstract]   [Full Text] [Related]  

  • 7. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.
    Greenland P; O'Malley PG
    Arch Intern Med; 2005 Nov; 165(21):2454-6. PubMed ID: 16314539
    [No Abstract]   [Full Text] [Related]  

  • 8. Lp-PLA2: a new marker of vascular risk.
    Med Lett Drugs Ther; 2003 Oct; 45(1167):83. PubMed ID: 14534508
    [No Abstract]   [Full Text] [Related]  

  • 9. Two markers complement each other in identifying risk.
    SoRelle R
    Circulation; 2004 Feb; 109(7):e9012. PubMed ID: 14981022
    [No Abstract]   [Full Text] [Related]  

  • 10. PLAC test for identification of individuals at increased risk for coronary heart disease.
    Hoogeveen RC; Ballantyne CM
    Expert Rev Mol Diagn; 2005 Jan; 5(1):9-14. PubMed ID: 15723587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lp-PLA2: an emerging biomarker of coronary heart disease.
    Dada N; Kim NW; Wolfert RL
    Expert Rev Mol Diagn; 2002 Jan; 2(1):17-22. PubMed ID: 11963798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting cardiovascular risk: so what do we do now?
    Lloyd-Jones DM; Tian L
    Arch Intern Med; 2006 Jul; 166(13):1342-4. PubMed ID: 16831997
    [No Abstract]   [Full Text] [Related]  

  • 13. [A simple measurement of plasma platelet-activating factor (PAF) acetylhydrolase, normal level of activity, and distribution among lipoprotein fractions].
    Kawamura Y; Satoh K; Takamatsu S; Mizuno S
    Rinsho Byori; 1987 Oct; 35(10):1149-53. PubMed ID: 3437547
    [No Abstract]   [Full Text] [Related]  

  • 14. Gauging cardiovascular risk with the PLAC test.
    Brown RA
    Nursing; 2006 Aug; 36(8):17. PubMed ID: 16888484
    [No Abstract]   [Full Text] [Related]  

  • 15. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein.
    Stafforini DM; Zimmerman GA; McIntyre TM; Prescott SM
    Trans Assoc Am Physicians; 1992; 105():44-63. PubMed ID: 1309005
    [No Abstract]   [Full Text] [Related]  

  • 16. Markers of inflammation and their clinical significance.
    Ballantyne CM; Nambi V
    Atheroscler Suppl; 2005 May; 6(2):21-9. PubMed ID: 15823493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
    Koenig W; Twardella D; Brenner H; Rothenbacher D
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1586-93. PubMed ID: 16627803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced PAF-acetylhydrolase activity is associated with postinjury multiple organ failure. David A. Partrick, Ernest E. Moore, Frederick A. Moore, Walter L. Biffl, and Carlton C. Barnett. Shock 7:170-174, 1997.
    Nathan N; Denizot Y
    Shock; 1998 Mar; 9(3):231-2. PubMed ID: 9525332
    [No Abstract]   [Full Text] [Related]  

  • 19. Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer.
    Denizot Y; Truffinet V; Bouvier S; Gainant A; Cubertafond P; Mathonnet M
    Mediators Inflamm; 2004 Feb; 13(1):53-4. PubMed ID: 15203567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Catabolism of PAF and its regulation].
    Miwa M
    Tanpakushitsu Kakusan Koso; 1991 Feb; 36(3):352-62. PubMed ID: 2024018
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.